PL1879566T3 - kompozycje i sposoby hamowania wydzielania kwasu żołądkowego - Google Patents

kompozycje i sposoby hamowania wydzielania kwasu żołądkowego

Info

Publication number
PL1879566T3
PL1879566T3 PL05780180T PL05780180T PL1879566T3 PL 1879566 T3 PL1879566 T3 PL 1879566T3 PL 05780180 T PL05780180 T PL 05780180T PL 05780180 T PL05780180 T PL 05780180T PL 1879566 T3 PL1879566 T3 PL 1879566T3
Authority
PL
Poland
Prior art keywords
compositions
methods
gastric acid
acid secretion
inhibiting gastric
Prior art date
Application number
PL05780180T
Other languages
English (en)
Inventor
Aleksey Kostadinov
Ayelet David
Sabina Glozman
Original Assignee
Vecta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1879566(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vecta Ltd filed Critical Vecta Ltd
Publication of PL1879566T3 publication Critical patent/PL1879566T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05780180T 2005-05-11 2005-07-28 kompozycje i sposoby hamowania wydzielania kwasu żołądkowego PL1879566T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67966405P 2005-05-11 2005-05-11
EP05780180.5A EP1879566B1 (en) 2005-05-11 2005-07-28 Compositions and methods for inhibiting gastric acid secretion
PCT/IB2005/002223 WO2006120500A1 (en) 2005-05-11 2005-07-28 Compositions and methods for inhibiting gastric acid secretion

Publications (1)

Publication Number Publication Date
PL1879566T3 true PL1879566T3 (pl) 2015-01-30

Family

ID=37396225

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05780180T PL1879566T3 (pl) 2005-05-11 2005-07-28 kompozycje i sposoby hamowania wydzielania kwasu żołądkowego

Country Status (16)

Country Link
US (2) US7803817B2 (pl)
EP (1) EP1879566B1 (pl)
JP (1) JP5161071B2 (pl)
KR (2) KR101421994B1 (pl)
CN (1) CN101184482B (pl)
AU (1) AU2005331689B2 (pl)
CA (1) CA2607803C (pl)
DK (1) DK1879566T3 (pl)
ES (1) ES2482771T3 (pl)
HK (1) HK1120421A1 (pl)
IL (1) IL187236A (pl)
PL (1) PL1879566T3 (pl)
RU (1) RU2385154C2 (pl)
TW (1) TWI388316B (pl)
WO (1) WO2006120500A1 (pl)
ZA (1) ZA200709745B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
PL226695B1 (pl) * 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
SE0602446L (sv) * 2006-11-16 2008-05-17 Entress Ab Ny användning av kända farmakologiskt aktiva kemiska sammansättningar
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN102014888A (zh) * 2007-07-03 2011-04-13 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
US8173158B2 (en) * 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
AU2008343787B2 (en) * 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
ES2370790B2 (es) * 2010-05-25 2012-10-18 Universidade De Santiago De Compostela Uso de oxalacetato en el tratamiento de isquemia.
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8568776B2 (en) 2011-02-11 2013-10-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RU2647462C2 (ru) 2013-04-23 2018-03-15 ЗедЭкс ФАРМА, ЭлЭлСи Композиция, состоящая из множества частиц, покрытых кишечнорастворимой оболочкой и имеющих белковую внутреннюю оболочку
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3123234A1 (en) 2018-12-20 2020-06-25 Colgate-Palmolive Company Oral care composition comprising zinc and an amino acid for treating symptoms of a gastric disorder in the oral cavity
CN114315750B (zh) * 2020-09-29 2024-05-10 鲁南制药集团股份有限公司 一种莫沙必利-丁二酸共晶

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2343011A (en) 1941-07-11 1944-02-29 Huppert Oskar Thio-protein plastic
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS60193917A (ja) 1984-03-14 1985-10-02 R P Shiila- Kk 多重構造軟カプセル剤
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
IL88507A (en) 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
JP2656338B2 (ja) * 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
CA2015981A1 (en) 1989-05-10 1990-11-10 Thomas H. Brown Compounds
US5048353A (en) 1990-03-01 1991-09-17 Beloit Corporation Method and apparatus for roll profile measurement
JPH03287103A (ja) 1990-04-02 1991-12-17 Seiko Epson Corp カラーフィルターの形成法
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
DE69131627T2 (de) 1990-06-20 2000-04-27 Astra Ab Soedertaelje Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
JPH06510547A (ja) 1992-07-06 1994-11-24 コミスサローバ，イリナ　アレクセエフナ 抗アルコール活性を有し、エネルギー代謝と胃粘膜の酸を生成し分泌する機能とを刺激し、放射能防御活性と抗コレラ活性を有する医薬組成物
US7795239B2 (en) 1992-07-27 2010-09-14 Mueller Medical International LLC Saccharide compositions and method of use
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
US5750531A (en) * 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5677302A (en) * 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
WO1999029320A1 (en) * 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
JP2003522105A (ja) 1998-06-18 2003-07-22 チョワース、ミッチャル、ワイ． ヘリコバクター・ピロリ（Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ）関連疾患治療用医薬組成物
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US7365047B1 (en) 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US20030049204A1 (en) 2001-04-24 2003-03-13 Mcgill University Individualization of therapy with gastroesophageal reflux disease agents
US6298876B1 (en) * 2001-05-02 2001-10-09 Ozone Industries, Inc. Quick disconnect coupling
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US20030175360A1 (en) * 2002-02-22 2003-09-18 Renzo Luzzatti Symptomatic relief of gastrointestinal disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2003086267A2 (en) 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
WO2003103592A2 (en) 2002-06-06 2003-12-18 University Of Washington Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
JP2006500041A (ja) * 2002-09-24 2006-01-05 ガムリンク エー／エス 少なくとも２種類の異なる生分解性ポリマーを含有するチューインガム
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
WO2005020879A2 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
AU2003274355A1 (en) * 2002-10-24 2004-05-13 Micap Plc. Targeted delivery
GB2394895A (en) 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
US7211568B2 (en) * 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
EP1729743A1 (en) 2004-01-06 2006-12-13 Panacea Biotec Limited Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DK1799196T3 (en) 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
US7918908B2 (en) * 2008-04-30 2011-04-05 Venturedyne, Ltd. Dust collector with equalized cleaning performance

Also Published As

Publication number Publication date
IL187236A0 (en) 2008-06-05
CN101184482A (zh) 2008-05-21
HK1120421A1 (en) 2009-04-03
EP1879566A4 (en) 2009-04-15
JP5161071B2 (ja) 2013-03-13
CA2607803A1 (en) 2006-11-16
KR20120051097A (ko) 2012-05-21
ZA200709745B (en) 2008-11-26
CA2607803C (en) 2013-12-17
JP2009502740A (ja) 2009-01-29
US7803817B2 (en) 2010-09-28
ES2482771T3 (es) 2014-08-04
TW200714278A (en) 2007-04-16
EP1879566A1 (en) 2008-01-23
IL187236A (en) 2016-07-31
KR20080005566A (ko) 2008-01-14
US9278080B2 (en) 2016-03-08
WO2006120500A1 (en) 2006-11-16
RU2007140941A (ru) 2009-06-20
AU2005331689A1 (en) 2006-11-16
RU2385154C2 (ru) 2010-03-27
US20060257467A1 (en) 2006-11-16
TWI388316B (zh) 2013-03-11
EP1879566B1 (en) 2014-03-12
US20100247634A1 (en) 2010-09-30
DK1879566T3 (da) 2014-06-10
AU2005331689B2 (en) 2011-05-19
KR101447909B1 (ko) 2014-10-08
KR101421994B1 (ko) 2014-07-22
CN101184482B (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
IL187236A0 (en) Compositions and methods for inhibiting gastric acid secretion
EP2005957A4 (en) ACID SECRETION INHIBITOR
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
PL2137210T3 (pl) Nowy sposób i kompozycje
EP1865779A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING CACHEXIA
PL1940839T3 (pl) Pirydopirymidynonowe inhibitory PI3Kalfa
IL197555A0 (en) Phosphorescent compositions and methods for identification using the same
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
EP1960781A4 (en) COMPOSITIONS AND METHODS FOR DETECTING PHOSPHOMONOESTERS
ZA200803381B (en) Methods and compositions for improving gastrointestinal health
GB0522287D0 (en) Method and compositions
EP2217250A4 (en) IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
EP2049122A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING THE ANGIOGENESIS
HK1191861A1 (zh) 胃酸分泌的快速作用抑制劑
EP1968565A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING ANGIOGENESIS
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
GB0617171D0 (en) Novel compositions and methods
GB0605247D0 (en) Compositions and methods for immunisation
GB0524927D0 (en) Compositions and method
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
EP2296470A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING GASTRIC ACID SECRETION
ZA200709852B (en) Spiro-benzimidazoles as inhibitors of gastric acid secretion
KR100496606B1 (en) Composition for anti-cancer comprising poly- -glutamic acid
GB0412584D0 (en) Composition of matter
GB0511235D0 (en) Compositions and method